Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. - Wikidata - wikimedia - TriplyDB

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.

http://www.wikidata.org/entity/Q33588174

about

Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours.

P2860

Q47608030-A215B923-7DF7-4B3B-B7E0-2B15226ECDB3 Q47731752-276AD0D7-7656-4035-8526-4CD9C4C3C3A3 Q50229413-B1437659-ED1B-45B0-92F0-F9A8B32075E6 Q55226872-A45AD5FC-6637-4C8C-8CE2-3F4AACE58FDA

P2860

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.

http://www.wikidata.org/entity/Q33588174

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@ast

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@en

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@nl

type

label

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@ast

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@en

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@nl

prefLabel

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@ast

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@en

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@nl

P1433

Q33588174-4FF1028F-1E4A-4232-BC72-4664B3E430A7

P1476

Q33588174-51F84E76-1C20-4EF8-8661-89AC90E5C96E

P2093

Q33588174-01A20E1E-E692-4235-A4B1-7EE8D13B3A13

Q33588174-0C71654C-E62E-45A6-835A-4AB43DCA3CEF

Q33588174-28BA948D-ABC6-42D7-965F-B8B88ED6D359

Q33588174-2B9B8789-F080-46B6-B006-C1C5AAABF6A6

Q33588174-2D31BD5B-C546-4828-8E46-26D80A1CE083

Q33588174-4587EC2E-6BDB-478C-B051-7508241DFD6D

Q33588174-5F44E07B-D6A4-4C02-9351-CC65926BF2B0

Q33588174-9A521AF9-207C-4FB1-B72D-8C4C9A74AC41

Q33588174-9DFCCD51-C96D-4CEF-8C8D-1E1EB2F9EA16

Q33588174-CB1FEF67-9DE7-49CC-8443-BE6DBBBEE195

P2860

Q33588174-082FFCE0-988C-45CC-8404-0896973FE62C

Q33588174-10D5DC85-0C03-4FCB-A293-F7CC91769183

Q33588174-1B6B0DAB-DBB6-47D1-8ADF-AB6B598D43BE

Q33588174-22903C00-E458-4A10-85E4-F438DE227433

Q33588174-29F04D63-2C2A-47AF-B2C3-5169F20A7AD2

Q33588174-2B452DB4-5CD0-4E83-BEF7-9DF732487809

Q33588174-3844E391-B38D-4A73-9F07-4F2EF85D689D

Q33588174-3A0EDF20-067D-4576-A277-904EC38DD8B0

Q33588174-3B1016FB-B50F-4522-9F5B-15B24DD4742E

Q33588174-47765A62-9DAB-4686-BB6D-80BA72D090B0

P304

Q33588174-D276EF72-617D-47B2-A0BF-0F5D9670932D

P31

Q33588174-331E1D10-4639-4296-AEAB-FEBDB9C00529

P356

Q33588174-17F53449-54C0-41FD-AA4A-E0EEF8174331

P433

Q33588174-1818D423-88B7-4A06-8175-5A2303DFC75F

P478

Q33588174-2C97D2F9-1CB7-4EF5-9CC7-7F9AE86778E7

P50

Q33588174-09D9EC1A-B229-48F8-83EC-3C4E7CEC41A7

Q33588174-7B129666-1496-4A60-8F57-352F43A284EF

Q33588174-A29A1B87-F9D5-4FEB-A9F1-80AF35486A68

Q33588174-BD69C8CA-5F44-48B8-BCCD-35680C87E2D6

P577

Q33588174-E1244665-40F3-4B28-AFFF-6535AD9C7D29

P698

Q33588174-FBFC7A1D-C92A-4913-B7EE-8EEA7C52DC31

P932

Q33588174-F1B871BE-7762-47FD-8B2E-171E6B478C12

P356

P1433

P1476

Dual Somatostatin Receptor/FDG ...... with Prognostic Significance.

@en

P2093

Alexander Engel

http://www.w3.org/2001/XMLSchema#string

Connie Diakos

http://www.w3.org/2001/XMLSchema#string

Dale L Bailey

http://www.w3.org/2001/XMLSchema#string

David Lh Chan

http://www.w3.org/2001/XMLSchema#string

Edward Hsiao

http://www.w3.org/2001/XMLSchema#string

Elizabeth J Bernard

http://www.w3.org/2001/XMLSchema#string

Enid Eslick

http://www.w3.org/2001/XMLSchema#string

Jaswinder Samra

http://www.w3.org/2001/XMLSchema#string

Nick Pavlakis

http://www.w3.org/2001/XMLSchema#string

Paul J Roach

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Changing paradigms with molecular imaging of neuroendocrine tumors

Reporting results of cancer treatment

Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT).

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.

Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.

Gallium-68 DOTATATE Production with Automated PET Radiopharmaceutical Synthesis System: A Three Year Experience

Response evaluation of gastrointestinal stromal tumors.

The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

P304

1149-1158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/THNO.18068

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Geoffrey P Schembri

Mustafa Khasraw

Stephen J Clarke

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28435454

http://www.w3.org/2001/XMLSchema#string

P932

5399582

http://www.w3.org/2001/XMLSchema#string